“Previously, this mutation has been undruggable, but this is now changing.”
For this episode of “The Vitals,” we spoke with Kristin Barber, FNP-BC, AOCNP, Huntsman Cancer Institute, about understanding the MAP kinase signaling pathway and some of the ongoing trials targeting these mutations in gastrointestinal oncology.
Barber discussed some of the ongoing phase 1 trials she is participating in and how she hopes the results of these trials could change patient outcomes following targeted treatment.
Nivolumab/Chemo Improves Survival in Advanced Gastric/GEJ Cancer
March 14th 2024The use of nivolumab plus chemotherapy as a standard frontline treatment has been supported by recent data from the phase 3 CheckMate 649 trial for patients with gastric, gastroesophageal junction, and esophageal adenocarcinoma.